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Abstract
Protein misfolding in cells is avoided by a network of protein chaperones that detect misfolded
or partially folded species. When proteins escape these control systems, misfolding may result
in protein aggregation and amyloid formation. We here show that aggregation of the amyloi-
dogenic protein α-synuclein (αS), the key player in Parkinson’s disease, is controlled by the
copper transport protein Atox1 in vitro. Copper ions are not freely available in the cellular
environment, but when provided by Atox1, the resulting copper-dependent ternary complex
blocks αS aggregation. Because the same inhibition was found for a truncated version of αS,
lacking the C-terminal part, it appears that Atox1 interacts with the N-terminal copper site in
αS. Metal-dependent chaperoning may be yet another manner in which cells control its
proteome.
Introduction
Systemic and tissue imbalances of metal levels are often found in neurodegenerative disorders
such as Parkinson’s disease (PD) (Fink, 2006), implying that metal ions may play roles in dis-
ease progression. A unifying molecular event in all neurodegenerative disorders is misfolding
and aberrant self-assembly of proteins into amyloid fibers with a hallmark cross-β-sheet
arrangement. Conformational changes resulting in aggregation of the neuronal protein
α-synuclein (αS) into amyloid fibers is directly related to PD (Galvin et al. 1999; Winner
et al. 2011). Many synthetic as well as naturally occurring molecules can modulate αS amyloid
formation in vitro, for example ring-fused two-pyridones (Horvath et al. 2012), other amyloi-
dogenic proteins (i.e., cross-reactivity) (Horvath & Wittung-Stafshede, 2016), bacterial
proteins (Chorell et al. 2015) and metal ions (Davies et al. 2016; Montes et al. 2014).
Copper (Cu) in both redox states (oxidized = Cu(II); reduced = Cu(I)) can bind to αS
(Camponeschi et al. 2013; De Ricco et al. 2015a) and structural features, binding sites, and
affinities for the interaction between αS and Cu(II), as well as Cu(I), have been the focus of
in vitro spectroscopic investigations (Binolfi et al. 2006, 2011; Camponeschi et al. 2013; De
Ricco et al. 2015a), Fig. 1a. Although most divalent cations can accelerate αS amyloid forma-
tion, Cu(II) has the largest such effect in vitro (Davies et al. 2016; Montes et al. 2014). Notably,
the effect of Cu(I) binding on αS amyloid formation in vitro has not been reported. It was
recently suggested that αS was able to act as a ferri-reductase, reducing iron using Cu(I)/Cu
(II) as a catalytic redox center (Brown, 2013) but it awaits to be revealed if Cu-mediated
redox reactions are related to αS function or merely part of a cascade of deleterious processes
(De Ricco et al. 2015b). It remains unknown how, and in what redox state, Cu would reach αS
in vivo. The cytoplasm is a reducing environment so most Cu ions are in the Cu(I) form
(Hatori and Lutsenko, 2013); in addition, there is no free Cu in cells (Ohrvik & Thiele,
2014; Tottey et al. 2005; Waldron et al. 2009).
In cells, Cu(I) is transported by copper transport proteins to specific targets that require Cu
for function (De Feo et al. 2009). Such an elaborate system is necessary for tight control of
metal distribution in time and space, and in order to keep Cu(I) soluble as free Cu(I) is chem-
ically instable. In the human cytoplasm, the Cu chaperone Atox1 (Fig. 1b), a small single-
domain protein with a CXXC (C, cysteine; X, any residue) Cu-binding motif (Boal &
Rosenzweig, 2009), brings Cu from the Cu importer Ctr1 in the plasma membrane to two
large, multi-domain P1B type ATPases in the Golgi membrane, ATP7A and ATP7B, for load-
ing of Cu-dependent enzymes (Lutsenkoet al. 2007). Movement of Cu(I) between these trans-
port proteins is facilitated by direct metal-bridged protein–protein complexes (Niemiec et al.
2015). Recently, new functions and partner proteins for Atox1 have been reported, implying
an extended functional repertoire (Blockhuys & Wittung-Stafshede, 2017; Blockhuys et al.
2017).
If alterations in Cu levels are a cause or a consequence in amyloidogenic diseases is unclear.
Perhaps Cu transport proteins deliver Cu(I) to αS such that, possibly requiring Cu(I) to Cu(II)
oxidation, aggregation is modulated? Or Cu transport proteins may instead be protective and
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remove Cu from αS before aggregation is triggered? We note that
Atox1 and other Cu transporters are expressed in most neuronal
cells (Davies et al. 2013; Montes et al. 2014); thus, interactions
with αS are feasible. To begin to address this knowledge gap,
we here tested if Atox1 can deliver Cu(I) to αS, and if so, what
are consequences on amyloid formation.
Materials and methods
Proteins
A construct with the wild-type αS gene was transformed into
BL21(DE3) (Novagen) cells. Cells were first grown to OD600 of 0.6
in LB containing 100 µg ml−1 carbenicillin at 37 °C and then
induced with 1 mM IPTG (isopropyl b-D-1-thiogalactopyranoside)
and grown overnight at 25 °C. The cells were lysed by sonication
in an ice bath through a sonicator probe in pulse mode (20 mM
Tris–HCl buffer, pH 8.0) in the presence of a protease inhibitor
cocktail (Roche). After sonication, the lysate was treated with a
universal nuclease (Pierce) for 15 min at room temperature. The
lysate was then heated at 90 °C for 10 min followed by centrifuga-
tion for 30 min at 15 000 g. After filtration through a 0.2 µm filter,
the sample was loaded on to pre-equilibrated 5 mL HiTrap Q FF
anion exchange column (GE Healthcare) and eluted by a linear
gradient of 1 M NaCl in 20 mM Tris–HCl buffer pH 8.0.
Fractions containing αS were combined and concentrated with
Ultra-15 Ultracel 10 K centrifugal filter devices (Millipore). The
concentrate was loaded on to Hiload 16/600 Superdex 75 pg col-
umn (GE Healthcare) and retrieved in 20 mM Tris–sulfate buffer
pH 7.4.
A pET3a construct (including a tag with a repressor protein
and a His-stretch followed by a Caspase 7 cleavage site) of the var-
iant αS A107C was transformed into BL21(DE3) (Novagen) cells,
which were then grown in similar conditions as for wild-type αS.
The cells were harvested by centrifugation and re-suspended in
Buffer A (20 mM Tris–HCl pH 8, 20 mM imidazole and 8 M
urea), then sonicated and centrifuged for 30 min at 15 000 g.
The supernatant was filtered through a 0.2 µm filter and applied
to pre-equilibrated 5 ml Hi Trap Ni-NTA column (GE healthcare)
with buffer A. After washing the column with 5 column volumes
of buffer B (20 mM Tris–sulfate pH 7.4, 20 mM imidazole,
50 mM NaCl), the protein was eluted with buffer B with
250 mM imidazole. The tag was cleaved by adding Caspase 7 in
the ratio of 1:100 (caspase 7: αS A107C w/w) in the presence of
5 mM TCEP (tris (2-carboxyethyl) phosphine) and incubated
overnight at 4 °C. The cleaved protein was loaded onto a 5 mL
HiTrap Q FF anion exchange column (GE Healthcare) and eluted
by a linear gradient of 1 M NaCl in 20 mM Tris-sulfate buffer, pH
7.4. The eluted fractions were pooled, concentrated and loaded
onto a Hiload 16/600 Superdex 75 column (GE Healthcare).
The purified protein was eluted in 20 mM Tris–HCl buffer pH
7.4 with 1 mM TCEP. Truncated αS (containing residues 1–97)
was expressed using the same vector (pET3a) as the A107C αS
mutant and the purification followed the same procedure. The
final gel filtration step was performed in 20 mM Tris–HCl buffer
pH 7.4. Purified CCS was obtained from the Umeå University
Protein Expertise Platform (http://www.kbc.umu.se/english/pep/
services/).
Until use, αS protein samples were frozen in liquid nitrogen
and stored at −80 °C. Purity for αS variants was confirmed by
single bands on SDS–PAGE and single elution peaks in SEC.
The concentrations of wild-type and A107C αS were deter-
mined using ε280 = 5960 M
−1 cm−1 (four Tyr; no Trp); ε280 =
1490 M−1 cm−1 was used for the truncated αS (one Tyr).
Atox1 in a pET21(b) vector was transformed into BL21(DE3)
plysS (Novagen) cells. Transformants were first grown to OD600 of
0.6 at 37 °C, and then induced with 1 mM IPTG and grown for
overnight at 25 °C. The cells were harvested by centrifugation
and re-suspended in Buffer A (20 mM MES, 1 mM EDTA,
1 mM TCEP, pH 5.7) containing protease inhibitor cocktail
(Roche), followed by sonication. The lysate was treated with a uni-
versal nuclease (Pierce) for 30 min at 4 °C and then centrifuged
for 30 min at 15 000 g. After filtration through a 0.2 µm filter,
the supernatant was loaded onto a pre-equilibrated 5 mL
HiTrap SP HP cation exchange column (GE Healthcare). The
protein was eluted by a linear gradient of buffer B (20 mM
MES, 1 mM TCEP, 1 M NaCl, pH 5.7). Fractions containing pro-
tein of the correct molecular weight were pooled and concentrated
with Ultra-15 Ultracel 3 K centrifugal filter devices (Millipore).
The concentrated protein sample was loaded on to Hiload
16/600 Superdex 75 pg column (GE Healthcare) and retrieved
in Chelex-treated storage buffer C (20 mM Tris-sulfate pH 7.4,
150 mM NaCl, 1 mM TCEP). The concentration of Atox1 was
determined using ε280 = 2980 M
−1 cm−1. Upon purification,
Atox1 is eluted in the apo-form. Cu(I)-loading of Atox1 is
achieved by the addition of equimolar Cu(II) in the presence of
5-fold excess 1,4-dithiothreitol (DTT), as previously reported
(Niemiec et al. 2012, 2015).
Amyloid formation assay
αS amyloid formation reactions were conducted in 96-well half-
area transparent bottom plates with a non-binding (non-ionic
hydrophilic) surface (Corning, CLS3881) with one 2-mm glass
bead in each well using a plate reader-incubator instrument
(BMG Labtech, Fluostar Optima). Time-resolved measurements
Fig. 1. (a) Scheme of αS sequence (key parts noted) with Cu-binding sites indicated.
(b) Structure of Atox1 with Cu ion and Cu-coordinating Cys highlighted (1TL4).
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were performed in TBS (0.05 M Tris–HCl buffer, pH 7.4 with
0.15 M NaCl; 93 318 Sigma-Aldrich) buffer in the presence of
20 µM Thioflavin T (ThT; T3516 Sigma-Aldrich) at 37 °C using
200 rpm agitation for 5 min during the 20 min measurement
cycles. Samples were typically incubated for 60 h and fluorescence
measured every 20 min. ThT was excited at 440 nm and emission
was recorded at 480 nm. All ThT experiments were performed in
triplicate at each time and repeated at least three independent
times.
Atomic force microscopy (AFM)
Aggregated samples from ThT experiments were diluted into
MilliQ water (10–20 times) and deposited on freshly cleaved
mica. After 10 min, the mica was rinsed with filtered Milli-Q
water and dried under a gentle nitrogen stream. Images were
recorded on an NTEGRA Prima setup (NT-MDT) using a gold-
coated single crystal silicon cantilever (NT-MDT, NSG01, spring
constant of ∼5.1 N/m) and a resonance frequency of ∼180 kHz.
512-pixel images were acquired with 0.5 Hz scan rate. Images
were analyzed using the WSxM 5.0 software(Horcas et al. 2007).
Size exclusion chromatography (SEC)
500 µl of samples containing 70 µM αS and/or 70 µM apo- or
holo-Atox1 were injected on a Superdex 75 10/300 column (GE
Healthcare) using an Äkta purifier (GE healthcare) system.
Running buffer was 20 mM TRIS pH 7.6 with 150 mM NaCl
and 350 µM DTT. Pre-mixing of Cu(II), DTT and apo-Atox1,
results in Cu(I) loading of the protein, i.e., Cu-Atox1 (Niemiec
et al. 2012, 2015). Elution profiles were probed by absorbance
at two wavelengths in parallel: 280 nm (protein) and 254 nm
(sulfur-to-Cu charge transfer). 1 ml fractions were collected and
sent for metal analysis by ICP-MS (Chalmers ICP-MS facility).
SEC was also used to quantify the amount of soluble αS after
aggregation reactions. For such analysis, the aggregated samples
were spun down (12 000 g, 15 min) and the supernatant loaded
on the Superdex 75 10/300 column using the same conditions
as for the fresh protein mixtures. The amount of αS was deter-
mined by peak intensity at 280 nm at the 9.5 ml elution volume
corresponding to αS. The samples were also analyzed for protein
content by SDS–PAGE electrophoresis.
Surface plasmon resonance (Biacore)
The αS Ala107Cys variant was biotinylated with Ez-Link
BMCC-Biotin (Cat. No.: 21900, Thermo Fisher Scientific) follow-
ing the manufacturer’s instructions. After the reaction, the mixture
was loaded on an Enrich70 24 ml SEC (BioRad) using an NGC
chromatography system (BioRad) to remove excess biotin.
Biotinylated αS was immobilized on one channel of a streptavidin-
coated sensor chip SA (GE Healthcare) to a level of ∼1000 response
units. Samples were injected for 180 s pulses in 10 mM HEPES pH
7.4 buffer containing 150 mM NaCl. Measurements were per-
formed on a Biacore X100 instrument. The measured response
units were background corrected by subtracting signal of the non-
modified flow channel.
Results and discussion
Purified αS aggregates into amyloid fibers in vitro upon incuba-
tion at pH 7, 37 °C and, with agitation, αS (70 µM) aggregates
with a lag time of about 10–15 h, as determined using the ThT
assay (Fig. 2a). Addition of 1:1 molar ratio of Cu(II) speeds up
Fig. 2. (a) Representative ThT fluorescence curves probing amyloid formation of 70 µM αS alone (black), and in the presence of equimolar Cu(II) (blue), apo-Atox1
(green) and Cu-Atox1 (red). (b) Analysis of ThT emission at 60 h for different αS/Atox1 mixtures. Average values and standard deviations were calculated based on at
least four repetitions. (c) AFM images of aggregation end-products in A.
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aggregation (Fig. 2a), as expected. The presence of apo-Atox1 has
only a small delaying effect on the lag time for aggregation,
whereas Cu(I)-loaded Atox1 distinctly reduced αS amyloid
formation in a concentration-dependent manner (Fig. 2a,b).
Atomic force microscopy (AFM) revealed the presence of typical
αS amyloids for samples with only αS, αS in the presence of Cu
(II), and αS with apo-Atox1. In contrast, but in accord with the
ThT data, in the presence of Cu(I)-Atox1, no αS amyloids were
detected by AFM (Fig. 2c). Notably, aggregation experiments in
the presence of Cu(I) (without Atox1, e.g. as a Cu(I)-DTT com-
plex) are technically challenging, as Cu(I) will oxidize and/or pre-
cipitate during these typically 1–2 days long experiments. Instead,
we used silver ions (Ag(I)) as a redox-inert model for Cu(I) ions
that is stable in solution. Because the presence of equimolar
AgNO3 did not affect αS amyloid formation (Fig. S1A), it appears
that the inhibitory effect of Cu-Atox1 arises due to the ternary
complex formation, and not Cu(I) delivery to αS.
As a complement to the AFM (lack of observable amyloids)
and ThT emission (low emission implying no amyloids) data
for αS mixed with Cu-Atox1, quantification of soluble αS after
aggregation experiments showed that there was much more
monomeric αS when it was incubated with Cu-Atox1 as com-
pared with when incubated alone or with apo-Atox1 (Fig. S2A).
As a test of specificity, we probed the effect of another cytoplas-
mic Cu-chaperone, the copper chaperone for superoxide dismut-
ase (CCS), on αS amyloid formation. However, the presence of
Cu-loaded CCS had no effect on αS amyloid formation
(Fig. S2B), implying that the Cu(I)-Atox1-mediated inhibition
of αS aggregation is protein specific.
To test for direct interaction of Cu-Atox1 with αS, we turned
to surface plasmon resonance (Biacore). Using αS attached to the
surface of a Biacore chip via cysteine-modification, Atox1 binding
was detected as an increase in the response signal which corre-
sponds to the mass of bound material. Whereas apo-Atox1 did
not interact with αS, we found a concentration-dependent inter-
action between αS and Cu(I)-Atox1 in the Biacore experiments.
By fitting concentration-dependent endpoint response values, a
dissociation constant for the Cu-Atox1/αS complex of around
5 µM was determined (Fig. 3a, Fig. S1B).
To probe the protein–protein pair further, we analyzed
Cu-Atox1/αS mixtures with SEC. Initial mixtures contained con-
centrations of proteins similar to in the ThT aggregation experi-
ments, which are then diluted during chromatography. SEC
traces probed at 280 nm (protein) and 254 nm (254/280 nm
ratio probes Cu-loading of Atox1 ( Niemiec et al. 2012, 2015);
ligand-to-metal charge transfer) showed that samples that had
been subjected to agitation and incubation, i.e., ‘amyloid inhibi-
tory condition’ contained significant fractions of monomeric αS
(cf. Fig. S2A) and Atox1, in accord with no amyloid formation.
SEC analysis of freshly mixed samples, mimicking the Biacore
experiments, showed the absence of a detectable Cu-Atox1/αS
complex but according to the 254/280 nm ratio of the resulting
Atox1 peak, Cu had been removed from Atox1 (Fig. S3).
Inductively coupled plasma mass spectrometry (ICP-MS) elemen-
tal analysis of Cu in the αS fractions (cannot be determined via
254/280 nm absorption ratio) from Cu-Atox1/αS mixtures
revealed increased amounts of Cu in αS; thus, some Cu had
moved from Atox1 to αS (Fig. 3b). Because the eluted protein
fractions contain protein in concentrations near the determined
dissociation constant for the Cu-Atox1/αS complex, it is reason-
able that the Cu-Atox1/αS complex detected in Biacore dissociates
when running through SEC. If Cu is bridging the ternary
complex, it is indeed reasonable that some Cu is found in αS
upon dissociation.
Our findings suggest that Cu(I)-loaded Atox1 can form a Cu
(I)-dependent complex with αS monomers that results in block-
age of αS amyloid formation (Fig. 4). The apo-form of Atox1
may interact weakly with αS, and this appears to delay aggregation
to some extent. The Atox1–Cu–αS complex appears to involve
bridging of Cu(I), as, if the complex is dissociated (eg. during
SEC), some of the Cu(I) is then found in αS. Cu(I) can bind to
sites in both N- and C-termini in αS (Binolfi et al. 2006, 2011;
Camponeschi et al. 2013; De Ricco et al. 2015a), see Fig. 1a. In
aggregation experiments with a truncated variant of αS (αS
Fig. 3. (a) Binding data from Biacore experiments for the interaction of Cu-Atox1 with
an αS-coated surface. (b) Cu content (shown as % of total protein, assuming one Cu
per protein) determined by ICP-MS for the αS peak eluted on a Superdex 75 column
of αS alone and the mixture αS + Cu-Atox1.
Fig. 4. Cartoon illustration of the main conclusion of this study, i.e., that Cu-loaded
Atox1 blocks monomeric αS from aggregation into amyloid fibers in vitro.
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residues 1–97; i.e., lacking the C-terminal 43 residues), we found
Cu(I)-Atox1 to inhibit the amyloid formation of the αS variant
but apo-Atox1 had no effect (Fig. S4). Because these results are
similar to those found for wild-type αS, we propose that Cu
(I)-Atox1 interacts with the N-terminal Cu(I) site of αS. This
interaction may sterically block assembly of core regions of αS
into amyloid fibers, but further mechanistic studies are desired.
In conclusion, we propose that metal-dependent chaperoning,
exemplified by Cu(I)-Atox1, may be another cellular mechanism,
in addition to the protein chaperone network, that controls the
proteome. In similarity with respect to the outcome but opposite
in terms of the role of the metal, metallothioneins can scavenge
Cu(II) and Zn(II) from amyloidogenic peptides and protect
against aggregation (Atrian-Blasco et al. 2017; Okita et al.
2017). For the specific case of PD, a significant decrease in total
tissue Cu in substantia nigra has been reported (Davies et al.
2014; Okita et al. 2017). In addition to perturbing the antioxidant
activity of Cu-dependent SOD1, our results imply that this reduc-
tion in tissue Cu may also abolish a Cu(I)-dependent chaperoning
ability of Atox1; both being alterations that would further pro-
mote PD.
Box: speculation
In addition to the myriad of well-established chaperone and chap-
eronin proteins that aid in protein folding and quality control, we
propose that metal-dependent chaperoning, here shown for a cyto-
plasmic copper chaperone, is an additional cellular process that
modulates and controls the proteome. We speculate that interac-
tions between the copper chaperone Atox1 and αS normally hold
back αS amyloid formation and this interaction may also deliver
copper ions to αS for (yet, unknown) metal-dependent αS func-
tions. In contrast, when cellular metal homeostasis and/or redox
status is disrupted, metal-dependent chaperone interactions may
be abolished and deleterious aggregation of amyloidogenic proteins
(such as αS) can flourish.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033583518000045
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